Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kamada Anti-SARS-CoV-2 in COVID-19 Hospitalized Patients
NCT04550325Phase 2Completed
- Sponsor
- Kamada Ltd.
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of anti-SARS-CoV-2 polyclonal immunoglobulin in COVID-19 pneumonia, sponsored by Kamada Ltd. Primary endpoint: Adverse events, serious adverse events, and deaths at 28 days. Started Aug 2020; status: completed.
02
Drugs
anti-SARS-CoV-2 polyclonal immunoglobulin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04550325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04550325.